Detalhe da pesquisa
1.
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.
Cell
; 178(3): 699-713.e19, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31280963
2.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620072
3.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
4.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821083
5.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108374
6.
Detection of interictal epileptiform discharges in an extended scalp EEG array and high-density EEG-A prospective multicenter study.
Epilepsia
; 63(7): 1619-1629, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35357698
7.
Intra- and Inter-Subject Perspectives on the Detection of Focal Onset Motor Seizures in Epilepsy Patients.
Sensors (Basel)
; 22(9)2022 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35591007
8.
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Br J Haematol
; 193(2): 325-338, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33605445
9.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107341
10.
Wearable devices for seizure detection: Practical experiences and recommendations from the Wearables for Epilepsy And Research (WEAR) International Study Group.
Epilepsia
; 62(10): 2307-2321, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34420211
11.
Mutations driving CLL and their evolution in progression and relapse.
Nature
; 526(7574): 525-30, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26466571
12.
Identification of Ictal Tachycardia in Focal Motor- and Non-Motor Seizures by Means of a Wearable PPG Sensor.
Sensors (Basel)
; 21(18)2021 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34577222
13.
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.
Genes Chromosomes Cancer
; 59(4): 261-267, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31677197
14.
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Blood
; 131(9): 955-962, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29255066
15.
Post-ictal accelerometer silence as a marker of post-ictal immobility.
Epilepsia
; 61(7): 1397-1405, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32459380
16.
Signal quality and patient experience with wearable devices for epilepsy management.
Epilepsia
; 61 Suppl 1: S25-S35, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32497269
17.
Day and night comfort and stability on the body of four wearable devices for seizure detection: A direct user-experience.
Epilepsy Behav
; 112: 107478, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33181896
18.
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.
Blood
; 129(1): 100-104, 2017 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27784674
19.
Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.
J Pathol
; 245(1): 61-73, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29464716
20.
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 19(9): 1215-1228, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30115596